Interfering in Medical Technology

DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round

... damages caused by these therapies. The innovative aspect of siDNA (signal interfering DNA) technology developed in DNA Therapeutics is to use a short fragment ... was founded in June 2006. Its original siDNA technology consists in interfering with DNA repair pathways that cancer cells use to resist radiotherapy and ...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

... as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination ....

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

... Celiac Celiac disease is an immune-mediated digestive disease that is triggered by the consumption of gluten and damages the small intestine, interfering with the absorption of nutrients from food. Gluten is a protein found in grains such as wheat, barley and rye. Symptoms of celiac disease will vary ...

Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications

... endothelial membrane in the BBB. NeuroTrans(TM) has also been conjugated to a variety of protein drugs, including enzymes and growth factors, without interfering with their therapeutic functions. About Raptor Pharmaceuticals Corp. Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding ...

NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device

... properties. NanoVibronix has created a platform that allows physicians to easily apply therapeutic ultrasound to assist in wound healing without interfering with any of the other modalities that are being utilized. Our simple-to-use, portable patch-based device can treat wounds in the hospital or at ...

Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

... as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination ....

Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials

... Previous research suggests that Viprinex may work in three ways to improve blood flow to areas of the brain affected by the stroke by: -- interfering with fibrinogen's ability to participate in blood clot formation, which should limit clot growth and reduce odds of reocclusion due to new clots. ...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

... and virosome technology licensed from Pevion Biotech Ltd. Mymetics' vaccine approach focuses on eliciting immune protection capable of interfering with late events of pathogen transmission, a generally accepted approach coupled, uniquely and most importantly, with early events of pathogen ...

Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy'

... NEW ROCHELLE, N.Y., Sept. 2 /PRNewswire/ -- The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to ...

September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging

... Diagnosed during an eye exam, cataracts develop slowly and may not hamper vision much at first. But when cataracts affect the quality of life -- interfering with driving or reading -- it's time to consider surgery, the only treatment. The most common surgical approach is called phacoemulsification. ...

Building a New and Better Ankle

... are gone -- Having advanced arthritis of the ankle ( http://orthoinfo.aaos.org/topic.cfm?topic=A00209#Cause ) -- The condition of your ankle is interfering with daily activities and causing pain Total ankle replacements can offer patients: -- Better motion of the ankle compared to fusion -- ...

Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma

... as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 230 patients have been treated with brostallicin in single-agent and combination ....

St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia

... in DNA synthesis, its components and repair of DNA. The identity of some of these genes was not surprising because the drug kills leukemia cells by interfering with their ability to replicate their DNA. When the researchers compared the gene expression patterns of patients who responded well to ...

Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data

... announced today further details of Dr. Raghavendra Mirmira's preclinical pancreatic islet cell research that was funded by the Company. Using a small interfering RNA (siRNA) against Senesco's Factor 5A technology, the data show what we believe to be a variety of promising results regarding delivery of ...

Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling

... as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination ....

Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models

... announced study results that demonstrated the company's RNAi Nanoplex (NPX) delivery technology platform is capable of effectively delivering small interfering RNAs (siRNAs) targeting both vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) pathways, two clinically validated pathways ...

New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit

... as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination ....

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease

... the pathophysiology of Alzheimer's disease is well documented, and a number of approaches have been studied which attempt to block their formation by interfering at critical stages in this complex pathway," said Hermona Soreq, Ph.D., Professor of Molecular Biology and Dean of Sciences at The Hebrew University. ...

Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development

... as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination ....

Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice

... that demonstrated the company's TargeTran(TM) delivery system is capable of delivering vascular endothelial growth factor (VEGF) targeted small interfering RNAs (siRNAs) that suppress tumor-induced angiogenesis by silencing target gene expression in mice. The study findings support the preclinical ...

New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.

... vaccines were similar in both groups, indicating that the rotavirus candidate vaccine can be co-administered with other routine vaccinations without interfering with the immune response to any of the administered vaccines. Results from the active phase of this study were included in GSK's Biologics License ...

Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)

... Lubiprostone, as a locally acting chloride channel activator, is being studied to evaluate if it may directly counteract this condition without interfering with the analgesic benefits of opioids. Should lubiprostone be approved as a treatment of OBD, Sucampo Pharmaceuticals believes it may fill an ...

Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD

... has equivalent efficacy in preventing vision loss as Genentech's Lucentis(R) administered every four weeks. Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the ...

'Use it or Lose it': A New Theory About Preserving Erectile Function After Prostate Surgery

... oxygen level causes some muscle cells in the penis's erectile tissue to lose their flexibility. The tissue gradually becomes more like scar tissue, interfering with the penis's ability to expand when it's filled with blood. Therefore, the traditional advice given to men -- to wait for erectile function to ...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

... a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic "backbone" of the siRNA. The polymer and ... design to design and create new, targeted siRNA therapeutics. Small interfering RNAs (siRNA) induce RNA interference, or RNAi, a naturally occurring ...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

... acting mu-opioid receptor antagonist that is designed to treat OIC without interfering with pain relief. Currently, there is no approved medication ... designed to mitigate the effect of opioids on peripheral receptors without interfering with central nervous system pain relief. Methylnaltrexone is being ...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

... of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the ...

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

... foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter ...

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

... foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter ...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

... range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural ...

Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

... foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm diameter ...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

... foundation for its two-part siRNA delivery system. The first component is a linear, cyclodextrin-containing polycation that, when mixed with small interfering RNA (siRNA), binds to the anionic "backbone" of the siRNA. The polymer and siRNA self-assemble into nanoparticles of approximately 50-80 nm in ...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

... medication is working and providing benefit, and 'on' time without troublesome dyskinesia which refers to 'on' time without involuntary movements interfering with function or causing discomfort, a common problem in Parkinson's disease. REQUIP XL 24-Hour significantly increased both 'on' time and 'on' ...

Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

... the pathophysiology of Alzheimer's disease is well documented, and a number of approaches have been studied which attempt to block their formation by interfering at critical stages in this complex pathway," commented Hermona Soreq, Ph.D., Professor of Molecular Biology and Dean of Sciences at The Hebrew ...

Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles

... One major difficulty impeding the wider development of RNAi-based therapies, however, is the need to deliver the molecules triggering RNAi (short interfering RNA) into the target cells and diseased tissues. Cequent's tkRNAi technology offers an elegant "Trojan horse" solution to the delivery problem; ...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

... proprietary technologies in targeted polymeric delivery systems and siRNA design to design and create new, targeted siRNA therapeutics. Small interfering RNAs (siRNA) use RNA interference, or RNAi, a naturally occurring mechanism within cells to selectively silence and regulate specific genes. The ...

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models

... agents. These compounds bind to tubulin protein, either in the monomer form or polymerized in microtubules, and prevent cancer cell proliferation by interfering with the microtubule dynamics required for cell division. This interference blocks the cell cycle sequence, leading to cell death (apoptosis). ...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

... range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural ...

Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy

... damage. It is equally important that they also not protect the cancer from radiotherapy. A compound that protected healthy normal cells while not interfering with tumor destruction could provide patients and physicians the ability to either reduce side effects from cancer radiotherapy or to increase ...